RGD Reference Report - Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. - Rat Genome Database

Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis.

Authors: Pepys, MB  Herbert, J  Hutchinson, WL  Tennent, GA  Lachmann, HJ  Gallimore, JR  Lovat, LB  Bartfai, T  Alanine, A  Hertel, C  Hoffmann, T  Jakob-Roetne, R  Norcross, RD  Kemp, JA  Yamamura, K  Suzuki, M  Taylor, GW  Murray, S  Thompson, D  Purvis, A  Kolstoe, S  Wood, SP  Hawkins, PN 
Citation: Pepys MB, etal., Nature 2002 May 16;417(6886):254-9.
RGD ID: 1300286
Pubmed: PMID:12015594   (View Abstract at PubMed)
DOI: DOI:10.1038/417254a   (Journal Full-text)

The normal plasma protein serum amyloid P component (SAP) binds to fibrils in all types of amyloid deposits, and contributes to the pathogenesis of amyloidosis. In order to intervene in this process we have developed a drug, R-1-[6-[R-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine-2-carboxyl ic acid, that is a competitive inhibitor of SAP binding to amyloid fibrils. This palindromic compound also crosslinks and dimerizes SAP molecules, leading to their very rapid clearance by the liver, and thus produces a marked depletion of circulating human SAP. This mechanism of drug action potently removes SAP from human amyloid deposits in the tissues and may provide a new therapeutic approach to both systemic amyloidosis and diseases associated with local amyloid, including Alzheimer's disease and type 2 diabetes.

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
amyloidosis  IMP 1300286; 1300286 RGD 
amyloidosis  ISOApcs (Mus musculus) and APCS (Homo sapiens)1300286 RGD 

Objects Annotated

Genes (Rattus norvegicus)
Apcs  (amyloid P component, serum)

Genes (Mus musculus)
Apcs  (amyloid P component, serum)

Genes (Homo sapiens)
APCS  (amyloid P component, serum)


Additional Information